S&P 500 Futures
(0.04%) 5 208.75 points
Dow Jones Futures
(0.18%) 39 066 points
Nasdaq Futures
(-0.14%) 18 170 points
Oil
(-0.36%) $78.20
Gas
(-0.46%) $2.19
Gold
(-0.40%) $2 321.80
Silver
(-0.44%) $27.49
Platinum
(-0.23%) $962.65
USD/EUR
(0.08%) $0.929
USD/NOK
(0.40%) $10.87
USD/GBP
(0.19%) $0.797
USD/RUB
(-0.17%) $91.19

实时更新: Consun Pharmaceutical [1681.HK]

交易所: HKSE 部门: Pharmaceuticals 工业: Drug Manufacturers—Specialty & Generic
最后更新时间7 May 2024 @ 16:08

3.82% HKD 6.25

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 16:08):

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China...

Stats
今日成交量 1.17M
平均成交量 786 395
市值 5.00B
EPS HKD0 ( 2024-03-28 )
下一个收益日期 ( HKD0 ) 2024-05-31
Last Dividend HKD0.300 ( 2023-06-08 )
Next Dividend HKD0 ( N/A )
P/E 5.90
ATR14 HKD0.00700 (0.11%)

音量 相关性

長: -0.24 (neutral)
短: 0.55 (weak)
Signal:(49.448) Neutral

Consun Pharmaceutical 相关性

10 最正相关
10 最负相关

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Consun Pharmaceutical 相关性 - 货币/商品

The country flag 0.01
( neutral )
The country flag -0.01
( neutral )
The country flag 0.00
( neutral )
The country flag 0.30
( neutral )
The country flag 0.69
( moderate )
The country flag 0.03
( neutral )

Consun Pharmaceutical 财务报表

Annual 2023
营收: HKD2.59B
毛利润: HKD1.92B (74.19 %)
EPS: HKD0.990
FY 2023
营收: HKD2.59B
毛利润: HKD1.92B (74.19 %)
EPS: HKD0.990
FY 2022
营收: HKD2.34B
毛利润: HKD1.76B (75.35 %)
EPS: HKD0.860
FY 2021
营收: HKD2.04B
毛利润: HKD1.53B (74.70 %)
EPS: HKD0.740

Financial Reports:

No articles found.

Consun Pharmaceutical Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0.300
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)

Consun Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.45 - good (84.50%) | Divividend Growth Potential Score: 5.71 - Stable (14.27%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend HKD0.0480 2014-09-25
Last Dividend HKD0.300 2023-06-08
Next Dividend HKD0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 19 --
Total Paid Out HKD2.25 --
Avg. Dividend % Per Year 0.00% --
Score 3.31 --
Div. Sustainability Score 8.45
Div.Growth Potential Score 5.71
Div. Directional Score 7.08 --
Next Divdend (Est)
(2024-06-24)
HKD0.334 Estimate 3.45 %
Dividend Stability
0.28 Very Poor
Dividend Score
3.31
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
2388.HK Ex Dividend Knight 2023-09-14 Semi-Annually 0 0.00%
1375.HK Ex Dividend Junior 2023-06-09 Annually 0 0.00%
0435.HK Ex Dividend Knight 2023-09-21 Semi-Annually 0 0.00%
6821.HK Ex Dividend Knight 2023-06-15 Annually 0 0.00%
1929.HK Ex Dividend Knight 2023-07-12 Semi-Annually 0 0.00%
0954.HK No Dividend Player 2023-05-22 Sporadic 0 0.00%
0071.HK Ex Dividend Knight 2023-09-25 Semi-Annually 0 0.00%
3311.HK Ex Dividend Knight 2023-06-19 Semi-Annually 0 0.00%
1522.HK Ex Dividend Junior 2023-06-29 Sporadic 0 0.00%
0564.HK Ex Dividend Knight 2023-06-07 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.3031.5003.945.91[0 - 0.5]
returnOnAssetsTTM0.1421.2005.256.30[0 - 0.3]
returnOnEquityTTM0.2271.5008.5910.00[0.1 - 1]
payoutRatioTTM0.416-1.0005.84-5.84[0 - 1]
currentRatioTTM2.860.8000.6920.554[1 - 3]
quickRatioTTM2.570.80010.008.00[0.8 - 2.5]
cashRatioTTM1.8381.5000.8981.347[0.2 - 2]
debtRatioTTM0.0929-1.5008.45-10.00[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM1.0182.009.6610.00[0 - 30]
freeCashFlowPerShareTTM0.9532.009.5210.00[0 - 20]
debtEquityRatioTTM0.141-1.5009.44-10.00[0 - 2.5]
grossProfitMarginTTM0.7421.0000.9680.968[0.2 - 0.8]
operatingProfitMarginTTM0.3191.0005.625.62[0.1 - 0.6]
cashFlowToDebtRatioTTM1.6011.0002.222.22[0.2 - 2]
assetTurnoverTTM0.4700.800-0.198-0.159[0.5 - 2]
Total Score8.45

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM5.691.0009.530[1 - 100]
returnOnEquityTTM0.2272.509.1010.00[0.1 - 1.5]
freeCashFlowPerShareTTM0.9532.009.6810.00[0 - 30]
dividendYielPercentageTTM8.111.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM1.0182.009.6610.00[0 - 30]
payoutRatioTTM0.4161.5005.84-5.84[0 - 1]
pegRatioTTM-0.07471.500-3.830[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3161.0004.600[0.1 - 0.5]
Total Score5.71

Consun Pharmaceutical

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。